Diversified Consumer Services
Company Overview of University of Cincinnati
University of Cincinnati is an educational institution that provides undergraduate, graduate, and honors programs. It offers courses in applied science; business administration; design, architecture, art, and planning; education; engineering; performing arts; and social work. The colleges of the university include College of Allied Health Sciences; College of Applied Science; College of Business Administration; College-Conservatory of Music College of Design, Architecture, Art & Planning; College of Education; College of Engineering; College of Evening & Continuing Education; College of Law; College of Medicine; College of Nursing; College of Pharmacy; McMicken College of Arts & Sciences; Sc...
2600 Clifton Avenue
Cincinnati, OH 45221
Founded in 1819
Key Executives for University of Cincinnati
Vice President of Development and Alumni Affairs and President of the University of Cincinnati Foundation
Senior Vice President of Academic Affairs and Provost
Director of the Department of Neurosurgery
Compensation as of Fiscal Year 2015.
University of Cincinnati Key Developments
University of Cincinnati Plans $2 Million Expansion of DAAP Shop Space
Apr 12 16
The University of Cincinnati is planning to expand its woodshop facilities in the College of Design, Architecture, Art and Planning. UC is proposing improvements that will reconfigure and expand the 3,000 level shop areas of the Edwin S. Wolfson Center for Environmental Design. As a result of growing enrollment and shop usage, the existing facilities for woodworking, welding, sculpting, painting, machining and foundry are overcrowded and ‘less than ideal in terms of work flows and student/staff safe operating perimeters’. The expansion and reconfiguration of the space would be a $2.1 million project. The areas that would receive upgrades total about 13,000 square feet. The project is expected to significantly increase the shop size and will displace the adjacent fine arts sculpture studio. The shop will be divided into heavy duty tools, light duty tools, machining, welding, foundry and CNC tools. In addition to the renovation work, the mechanical dust collection systems will be replaced with a new system.
University of Cincinnati to Pay $200,000 to Settle Lawsuit
Mar 25 16
University of Cincinnati announced that it will pay $200,000 to a nonprofit organization after settling a lawsuit that involved the stalled Emery Theatre redevelopment, according to court filings. Ohio Court of Claims Judge Patrick McGrath approved the settlement between UC and the Requiem Project. As part of the settlement, Requiem is dropping its lawsuit and UC does not admit liability to the nonprofit's claims, according to the court filing. UC will also pay court costs. Requiem has reached a separate settlement with Emery Center Corp. and Emery Center Apartments Limited Partnership, lessees of the Emery Theatre property from UC, said Requiem attorney Sean Callan.
Arch Biopartners Inc Enters into Exclusive License Agreement with the University of Cincinnati for AB569
Mar 16 16
Arch Biopartners Inc. announced that it has entered into an exclusive license agreement with the University of Cincinnati (UC) for AB569, a new candidate drug to treat Pseudomonas aeruginosa (P. aeruginosa) respiratory infections. Recent Developments in the AB569 program: In 2015, Arch management has worked with the lead inventor of AB569, Dr. Daniel Hassett at the University of Cincinnati (UC) College of Medicine, to build the patent portfolio for AB569 and to prepare a clinical development plan to test the safety and efficacy of the drug against P. aeruginosa respiratory infections in cystic fibrosis (CF) patients. The U.S. Food and Drug Administration granted orphan drug designation to Arch for AB569 in November, 2015. Arch has recently applied to the European Medicines Agency for a similar orphan drug designation for the European market and the application is currently under review. Earlier this month, Dr. Hassett and his collaborators, published details regarding the efficacy of AB569 in killing P. aeruginosa in the peer-reviewed journal Frontiers in Microbiology. Arch will pay UC a nominal one time fee for entering into the license. All other future payments are consistent with industry standard and will be based on clinical trial and revenue milestones reached by Arch in future. The Clinical Need for a New Treatment for P. aeruginosa Pulmonary Infections: P. aeruginosa is a significant cause of bacterial respiratory infections in patients who have cystic fibrosis (CF), pneumonia or chronic obstructive pulmonary disease (COPD). There are approximately 40,000 CF patients in the U.S. The mean prevalence of CF is approximately 0.74 cases per 10,000 people among 27 European Union countries, which is well below the defined limit for a rare or orphan disease. The mucoid form of P. aeruginosa, often found in CF patients, is a very challenging infection to treat due to its high resistance to both antibiotics and phagocyte-mediated killing. Once patients present with the mucoid form of P. aeruginosa, their overall lung function precipitously declines, resulting in a poor prognosis. Thus, there is an urgent clinical need for the development of novel effective treatments in this area. AB569 constitutes an innovative potential treatment for dealing with mucoid and nonmucoid P. aeruginosa pulmonary infections that are resistant to traditional antibiotics.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|